S100A4 and central nervous system cancer: Subsequent animal experiments and functional analyses demonstrated the roles of S100A4 in impeding immune response, including phagocytic activity of macrophages, production of IFN-γ and activation of T cells, thus favoring the growth of glioma, supporting S100A4 as a promising immunotherapeutic target (105).